The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.
Switching from intermittently scanned to real-time continuous glucose monitoring improves time in range by a clinically relevant percentage, show the findings of the 6-month ALERTT1 trial.